Atmofizer Techno Stock Price, News & Analysis

Atmofizer Technologies Inc. (traded over-the-counter under the symbol ATMFF and on the Canadian Securities Exchange under the symbol ATMO) is an industrial technology company focused on air purification and ultrafine particle control. Operating in the pollution and treatment controls space, Atmofizer develops consumer and industrial solutions based on patent-protected and patent-pending technology for ultrafine particle agglomeration and neutralization.

According to the company, its technology is designed to address nano-scale particles, viruses and bacteria that are too small to be effectively managed by conventional HEPA filters and ultraviolet lights. Atmofizer describes its approach as a way to improve air safety and purification efficiency while lowering customers' operational costs.

Core technology and air treatment approach

The company uses a process it refers to as "atmofizing" air. In this process, ultrasonic acoustic waves are used to agglomerate, or cluster together, very small airborne particles into larger targets. These larger clusters are then radiated by ultraviolet light to neutralize their harmful properties. The company states that this method can be applied to a wide range of dangerous nano-scale particles, including viruses, bacteria and industrial pollution.

Atmofizer reports that using devices that "atmofize" air in tandem with HEPA or high efficiency particulate air filters can make those filters work more efficiently. By clustering smaller particles into larger ones, existing filters may remove more material from the air, potentially enabling the use of less-powerful filters and resulting in cleaner, longer-lasting filters. The company also notes that this can reduce operating costs and make filters less of a health hazard to clean or replace.

Patents and intellectual property

Atmofizer highlights multiple U.S. patents and patent applications related to its technology. The company reports that the United States Patent and Trademark Office issued a U.S. patent relating to its air and water purification technology, and that it received a Notice of Allowance for an application titled "Ultra-Fine Particle Aggregation, Neutralization and Filtration" (US Patent Application No. 11,291,939). This application is described as providing broad protection for important aspects of Atmofizer's air purification technology, including a design aimed at delivering ultra-fine particle agglomeration and nanoparticle reduction performance in larger air ducts with faster-moving air, using fewer parts.

The company also reports that this allowed application was followed by a formal patent issuance, identified as U.S. Patent No. 11,478,742, which it associates with integrated and HVAC applications. Atmofizer describes itself as the patent-pending and patent-protected sole source of technology to "atmofize" air, and it indicates that it intends to market its patents to be licensed by air purification device manufacturers, HVAC suppliers and service companies.

Products, applications and markets

Atmofizer states that it applies its proprietary technology in consumer and industrial air purification products manufactured under the Atmofizer brand, as well as in retail and commercial devices produced by other companies that integrate Atmofizer technology under license. The company describes its owned and licensed product lines as covering:

• Wearable, portable and mobile devices for personal air treatment
• Larger systems designed to handle higher air volumes for commercial, industrial, institutional and residential applications

In addition to standalone air purifiers, Atmofizer reports ongoing development for forced air (HVAC) markets. The company has described efforts to integrate its agglomeration technology into existing forced air systems, including designs intended for installation in air ducts. It has reported work on prototypes and testing at an accredited third-party lab, focusing on performance in larger air ducts with faster-moving air.

Atmofizer has also discussed a transition of its business focus toward what it describes as its most valuable addressable market in HVAC applications. In its communications, the company has outlined a strategy summarized as "Prove it, Protect it, Promote it"—referring to demonstrating performance, securing intellectual property protection, and marketing or licensing the technology.

HVAC integration and partnerships

The company reports that it has been working with HVAC service providers in the United States to validate product-market fit and develop production designs for HVAC-integrated solutions. Atmofizer has described a design that can be installed by HVAC service technicians and that is intended to improve filter performance and HVAC operation by enhancing removal of ultra-fine and fine particles from the air.

Atmofizer has also indicated that its HVAC solution is designed to be adapted for residential, commercial, industrial and agricultural applications. The company has communicated plans to pursue an asset-light approach by targeting existing HVAC suppliers and manufacturers that already have distribution and scale, with the goal of licensing its patented technology.

Testing and performance claims

In its public disclosures, Atmofizer has highlighted results from third-party laboratory testing of its technology. It has reported that testing of its airborne nanoparticle agglomeration engine in a lab environment showed reductions in airborne ultra-fine particles smaller than one micron and changes in the distribution of larger particles, which the company interprets as evidence of effective agglomeration.

Atmofizer has also cited third-party tests of its Atmofizer ONE technology, reporting a greater than 4-log reduction (greater than 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria and an enveloped virus used as a surrogate for SARS-CoV-2. The company states that these results were achieved after a period of continuous device operation and notes that the Atmofizer ONE is marketed subject to a U.S. Food and Drug Administration enforcement policy for sterilizers, disinfectant devices and air purifiers during the COVID-19 public health emergency. Atmofizer also notes that the FDA has not evaluated its technology and that Atmofizer ONE has not been reviewed or approved by the FDA.

Business model and licensing focus

Atmofizer describes its approach as an asset-light, technology-first strategy. The company emphasizes the development and protection of its clean technology, combined with efforts to license or partner with industry participants to scale adoption. In addition to selling its own branded devices, Atmofizer reports that it seeks to generate value by licensing its patented technology to air purification device manufacturers and HVAC suppliers and service companies.

The company has also referenced distribution and marketing relationships in its disclosures, including arrangements with distributors and service providers in North America. It has discussed efforts to align its marketing with regulatory frameworks, including U.S. Environmental Protection Agency and FDA guidance, in order to support commercialization of its air purifiers and related products.

Capital markets and corporate actions

Atmofizer has undertaken several capital markets activities. The company has established an at-the-market equity program that allows it to issue and sell common shares from treasury on a discretionary basis, with sales executed through the Canadian Securities Exchange or other marketplaces in Canada. It has reported issuing common shares under this program to raise proceeds for its operations.

The company has also implemented a share consolidation of its common shares on a twenty-for-one basis. Following this consolidation, Atmofizer noted that its name remained unchanged and that its trading symbol on the Canadian Securities Exchange continued as "ATMO". The consolidation affected the number of issued and outstanding common shares and proportionately adjusted the exercise or conversion terms of outstanding convertible instruments.

Business combination discussions with House of Doge

In a later development, Atmofizer announced that it had entered into a definitive business combination agreement with House of Doge Inc. and a merger subsidiary. Under that agreement, Atmofizer was expected to acquire House of Doge in a stock-for-stock reverse-takeover transaction, with plans for the combined company to carry on the business of House of Doge, change its name to "House of Doge Inc." or another agreed name, and apply to delist from the Canadian Securities Exchange and seek listings on Cboe Canada and Nasdaq. The agreement contemplated various corporate changes, including a new class of non-voting common shares, a merger of House of Doge into the merger subsidiary, and a registration statement with the U.S. Securities and Exchange Commission.

However, Atmofizer later announced that Atmofizer, House of Doge Inc. and Doge Merger Sub, Inc. mutually agreed to terminate this business combination agreement. As a result, the proposed transaction did not proceed under the terms originally announced.

Industry context

Within the broader pollution and treatment controls and air purification space, Atmofizer positions its technology around ultrafine particle agglomeration and neutralization, with applications in standalone devices and HVAC-integrated systems. Its disclosures emphasize patented technology, third-party testing, and a licensing-oriented model that targets consumer, commercial, industrial, institutional and residential environments.